Dr Adnan Khan

Dr Adnan Khan steps down from Advisory Board

We would like to offer our sincere thanks to Dr Adnan Khan for his four years of service as a member of the CDT Advisory Board. He is stepping down from the Advisory Board to focus on his new position in the New Medicines Division of UCB Celltech in Slough.

Adnan completed his PhD in 2012 as part of the EPSRC/AstraZeneca-sponsored CDT in Targeted Therapeutics, under the supervision of Prof. David Pritchard, Prof. Sue Watson (Nottingham) and Dr. Robert Wilkinson (AstraZeneca). Upon completing his PhD Adnan held a Postdoctoral Research Fellowship in Prof. Padraic Fallon’s Translational Immunology Group in the School of Medicine at Trinity College Dublin.